Literature DB >> 7916973

Human relaxins in normal, benign and neoplastic breast tissue.

L S Tashima1, G Mazoujian, G D Bryant-Greenwood.   

Abstract

Immunoreactive relaxin is present in human breast cyst fluid and postpartum milk without concurrent detectable serum levels, suggesting that the breast is a site of relaxin synthesis. Monoclonal and polyclonal antibodies to human relaxin H2 have been used to immunolocalize relaxins in normal, benign and neoplastic breast tissues with the avidin-biotin immunostaining technique. In view of the similarities in amino acid sequence between H1 and H2 relaxins, these antibodies to H2 relaxin are likely to detect either or both relaxins present in tissue sections. Staining patterns with these antibodies were identical and showed positive diffuse cytoplasmic staining in normal, lobular and ductal epithelium and in myoepithelial cells in breast tissues from normal prepubertal, cyclic, gestational, lactational and postmenopausal females. Relaxin staining was also present in epithelial and myoepithelial cells of ducts and lobules in benign breast disease as well as in metaplastic epithelium of apocrine microcysts. All breast carcinomas (infiltrating ductal, tubular, medullary, intraductal and infiltrating lobular carcinomas) had strong uniform cytoplasmic staining within the neoplastic epithelial cells. All staining was abolished in normal and neoplastic tissues when the polyclonal antibody was preabsorbed with relaxin. It was necessary to distinguish between the possibilities of relaxins being sequestered by breast tissue and local synthesis. Therefore, the expression of the H1, H2 or both human relaxin genes in normal and neoplastic breast tissues was studied by the isolation of RNA, synthesis of first strand cDNA and amplification by PCR using primer sets which amplified either both H1 and H2, or specifically only H1 or H2 relaxin. The coamplification of both relaxin genes was verified by Southern analysis, diagnostic restriction enzyme digestion and sequencing. The primer set for H1 relaxin detected H1 gene expression in 1 out of 8 normal and 9 out of 12 neoplastic breast RNA samples. The H2 relaxin gene was found to be expressed in 3 out of 8 of the normal samples but in all 12 of the neoplastic samples, suggesting that this gene is expressed at higher copy number in the neoplastic tissues. This is the first demonstration of the cellular immunolocalization of relaxin and relaxin gene expression in normal and neoplastic breast. This should allow further exploration of relaxin's role(s) in normal breast physiology and in its tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916973     DOI: 10.1677/jme.0.0120351

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  9 in total

Review 1.  Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Authors:  Elizabeth Ann L Enninga; Shernan G Holtan; Douglas J Creedon; Roxana S Dronca; Wendy K Nevala; Simona Ognjanovic; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

2.  Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.

Authors:  Sabine Hombach-Klonisch; Joanna Bialek; Bogusz Trojanowicz; Ekkehard Weber; Hans-Jürgen Holzhausen; Josh D Silvertown; Alastair J Summerlee; Henning Dralle; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.

Authors:  Alberto Ferlin; Luca De Toni; Marco Sandri; Carlo Foresta
Journal:  Br J Pharmacol       Date:  2016-05-05       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 5.  The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Authors:  Ting-Yun Chen; Xiaoyun Li; Ching-Hsia Hung; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-02-26       Impact factor: 2.183

6.  Immunoexpression of the relaxin receptor LGR7 in breast and uterine tissues of humans and primates.

Authors:  Richard Ivell; Marga Balvers; Yvonne Pohnke; Ralph Telgmann; Olaf Bartsch; Karin Milde-Langosch; Ana-Maria Bamberger; Almuth Einspanier
Journal:  Reprod Biol Endocrinol       Date:  2003-11-24       Impact factor: 5.211

7.  Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells.

Authors:  Yvonne Radestock; Cuong Hoang-Vu; Sabine Hombach-Klonisch
Journal:  Breast Cancer Res       Date:  2008-08-21       Impact factor: 6.466

Review 8.  RXFP1 is Targeted by Complement C1q Tumor Necrosis Factor-Related Factor 8 in Brain Cancer.

Authors:  Thatchawan Thanasupawat; Aleksandra Glogowska; Maxwell Burg; G William Wong; Cuong Hoang-Vu; Sabine Hombach-Klonisch; Thomas Klonisch
Journal:  Front Endocrinol (Lausanne)       Date:  2015-08-13       Impact factor: 5.555

9.  Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain.

Authors:  Claudia Binder; Eugenia Chuang; Christina Habla; Annalen Bleckmann; Matthias Schulz; Ross Bathgate; Almuth Einspanier
Journal:  Clin Exp Metastasis       Date:  2013-08-21       Impact factor: 5.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.